drugset
Drugs / Emavusertib
last change Aug 2026 re-read 2 minutes ago

Emavusertib

also known as CA-4948 · AU-4948 · CA-4948 hydrochloride · CA-4948 maleate · CA-4948 mesylate · CA-4948 tosylate · CA-4948-phosphate · EMAVUSERTIB (CA-4948) · +5 more

Small molecule targets IRAK4 via inhibition

Developed for
myelodysplastic syndrome · acute myeloid leukemia · anemia · B-cell chronic lymphocytic leukemia · biliary tract cancer · colorectal adenocarcinoma · esophageal cancer · gastric cancer
+5 more · gastroesophageal cancer · metastatic malignant neoplasm in the brain · pancreatic ductal adenocarcinoma · primary central nervous system lymphoma · urothelial carcinoma
Investigated by
Curis, Inc. · National Cancer Institute (NCI) · Washington University School of Medicine · Merck Sharp & Dohme LLC · The Foundation for Barnes-Jewish Hospital · University of Florida
+1 more · University of Leipzig

Trials 12 · a red edge is where a trial was stopped

today NCT07463820 · Ph 2 NCT07271667 · Ph 2 NCT07107750 · Ph 1 NCT06696768 · Ph 1 NCT06439836 · Ph 1 NCT05669352 · Ph 1/2 NCT05564390 · Ph 2 NCT05685602 · Ph 1 NCT05187182 · Ph 1 NCT05178342 · Ph 2 NCT04278768 · Ph 1/2 NCT03328078 · Ph 1/2
2018201920202021202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT07107750 Mar 2026 → Jun 2030 expected biliary tract cancer Washington University School of Medicine Recruiting No outcome recorded
Phase 1 NCT06696768 Jun 2025 → Dec 2026 expected colorectal adenocarcinoma National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 1 NCT06439836 May 2025 → Jun 2027 expected urothelial carcinoma National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 1 NCT05685602 Jun 2023 → Apr 2027 pancreatic ductal adenocarcinoma National Cancer Institute (NCI) Suspended No outcome recorded
Phase 1 NCT05187182 Jun 2023 → Jul 2028 expected esophageal cancer, gastric cancer, gastroesophageal cancer Washington University School of Medicine Recruiting No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT05669352 Apr 2025 → Aug 2026 metastatic malignant neoplasm in the brain University of Florida Suspended No outcome recorded
Phase 1/2 NCT04278768 Jul 2020 → Apr 2026 acute myeloid leukemia, myelodysplastic syndrome Curis, Inc. Suspended No outcome recorded
Phase 1/2 NCT03328078 Dec 2017 → Aug 2026 overdue primary central nervous system lymphoma Curis, Inc. Recruiting No outcome recorded
Phase 24 trials
Phase 2 NCT07463820 Jun 2026 → Dec 2027 expected myelodysplastic syndrome National Cancer Institute (NCI) Not yet recruiting No outcome recorded
Phase 2 NCT07271667 Apr 2026 → Nov 2027 expected B-cell chronic lymphocytic leukemia Curis, Inc. Recruiting No outcome recorded
Phase 2 NCT05564390 Jun 2024 → May 2029 expected acute myeloid leukemia with multilineage dysplasia, myelodysplastic syndrome, therapy related acute myeloid leukemia and myelodysplastic syndrome National Cancer Institute (NCI) Recruiting No outcome recorded
Phase 2 NCT05178342 Jan 2022 → Jul 2024 anemia, myelodysplastic syndrome University of Leipzig Terminated No outcome recorded

Evidence & citations 18 cited values

Every value below carries the sentence it was read from. 13 sources stand behind the page.

FieldValueCited text
Known as Emavusertib ClinicalTrials.gov intervention name — accepted as the source's own label NCT07463820 ↗
8

NCT06696768 ↗

NCT07271667 ↗

NCT06439836 ↗

NCT05564390 ↗

NCT05685602 ↗

NCT04278768 ↗

NCT07107750 ↗

NCT03328078 ↗
Known as AU-4948 ChEMBL registry synonym — accepted as the source's own label CHEMBL4783351 ↗
Known as CA-4948 “CA-4948” NCT03328078 ↗
3

NCT05669352 ↗

NCT05187182 ↗

NCT05178342 ↗
Known as CA-4948 hydrochloride ChEMBL registry synonym — accepted as the source's own label CHEMBL4783351 ↗
Known as CA-4948 maleate ChEMBL registry synonym — accepted as the source's own label CHEMBL4783351 ↗
Known as CA-4948 mesylate ChEMBL registry synonym — accepted as the source's own label CHEMBL4783351 ↗
Known as CA-4948 tosylate ChEMBL registry synonym — accepted as the source's own label CHEMBL4783351 ↗
Known as CA-4948-phosphate ChEMBL registry synonym — accepted as the source's own label CHEMBL4783351 ↗
Known as EMAVUSERTIB (CA-4948) ChEMBL registry synonym — accepted as the source's own label CHEMBL4783351 ↗
Known as EMAVUSERTIB HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL4783351 ↗
Known as EMAVUSERTIB MALEATE ChEMBL registry synonym — accepted as the source's own label CHEMBL4783351 ↗
Known as EMAVUSERTIB MESYLATE ChEMBL registry synonym — accepted as the source's own label CHEMBL4783351 ↗
Known as EMAVUSERTIB PHOSPHATE ChEMBL registry synonym — accepted as the source's own label CHEMBL4783351 ↗
Known as EMAVUSERTIB TOSYLATE ChEMBL registry synonym — accepted as the source's own label CHEMBL4783351 ↗
Action Inhibit “Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4).” NCT04278768 ↗
Modality Small molecule “Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4).” NCT04278768 ↗
Route Oral “oral administration of emavusertib alone or in combination with ibrutinib” NCT03328078 ↗
Target IRAK4 “Emavusertib is a novel small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4).” NCT04278768 ↗